孟鲁斯特、氯雷他定、丹参酮联合治疗过敏性紫癜的细胞因子含量、免疫应答状态的评估

摘要

目的:评估孟鲁斯特、氯雷他定、丹参酮联合治疗过敏性紫癜的细胞因子含量、免疫应答状态.方法:收集2014年5月~2017年1月在陕西省安康市中心医院接受治疗的过敏性紫癜患者80例,按照随机数表法分为孟鲁斯特组、氯雷他定组、丹参酮组、联合治疗组各20例,对比4组患者治疗前后血清炎症因子、Th17/Treg细胞免疫指标含量的差异.结果:治疗前,4组患者血清中炎症因子、Th17/Treg细胞免疫指标含量的差异无统计学意义(P>0.05).治疗后,联合治疗组血清中高迁移率族蛋白1(HMGB1)、白介素(IL)-8、IL-14、IL-23、IL-33的含量低于孟鲁斯特组、氯雷他定组、丹参酮组(P<0.05);血清中IL-17的含量低于孟鲁斯特组、氯雷他定组、丹参酮组,IL-10、转化生长因子(TGF)-β的含量高于孟鲁斯特组、氯雷他定组、丹参酮组(P<0.05).结论:孟鲁斯特、氯雷他定、丹参酮联合治疗过敏性紫癜,有助于减轻全身炎症反应,均衡Th17/Treg细胞免疫.%Objective:To evaluate the cytokine levels and immune response status of the combination therapy of montelukast,loratadine and tanshinone for Henoch-Schonlein purpura.Methods:A total of 80 patients with Henoch-Schonlein purpura who were treated in Ankang Central Hospital between May 2014 and January 2017 were collected and divided into montelukast group,loratadine group,tanshinone group and combined treatment group according to the random number table,with 20 cases in each group.Serum levels of inflammatory factors,Th17/Treg cellular immunity indexes before and after treatment were compared among four groups of patients.Results:Before treatment,differences in serum levels of inflammatory factors and Th17/Treg cellular immunity indexes were not statistically significant among four groups of patients (P>0.05).After treatment,serum HMGB1,IL-8,IL-14,IL-23 and IL-33 levels in combined treatment group were lower than those in montelukast group,loratadine group and tanshinone group;serum IL-17 level was significantly lower than that in montelukast group (P<0.05),loratadine group and tanshinone group while IL-10 and TGF-β levels were significantly higher than those in montelukast group,loratadine group and tanshinone group (P<0.05).Conclusions:The combination therapy of montelukast,loratadine and tanshinone for Henoch-Schonlein purpura helps to reduce systemic inflammatory response and balance Th17/Treg cell immunity.